Cargando…
Cervical Acid Phosphatase: A Biomarker of Cervical Dysplasia and a Potential Surrogate Endpoint for Colposcopy
Background: In 2000, cervical acid phosphatase (CAP) has been recently described as a biomarker labeling abnormal squamous cells on Pap smears (USPTO #6,143,512). The enzyme activity is presented as a red, granular deposit on a modified Papanicolaou background. This unique property was utilized for...
Autores principales: | Markovic, Olivera, Markovic, Nenad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850803/ https://www.ncbi.nlm.nih.gov/pubmed/15258329 http://dx.doi.org/10.1155/2004/845798 |
Ejemplares similares
-
Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002) -
Colposcopy and additive diagnostic value of biopsies from colposcopy‐negative areas to detect cervical dysplasia
por: Baasland, Ingrid, et al.
Publicado: (2016) -
Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002) -
Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”
Publicado: (1998) -
2023 Canadian Colposcopy Guideline: A Risk-Based Approach to Management and Surveillance of Cervical Dysplasia
por: Willows, Karla, et al.
Publicado: (2023)